… Rishika Sadam (Reuters) -India’s Biocon expects a 50% drop in … illnesses such as cancer, rheumatoid arthritis, psoriasis and diabetes. The U … large comparative clinical efficacy trials. Biocon, which aims to cumulatively launch …

… company and subsidiary of Biocon announced that Health Canada … for an active psoriatic arthritis for adults and moderately … available through the My Biocon Biologics patient support program. … CEO & Managing Director, Biocon Biologics, said: “Health Canada’ …

… (6–17 years), active psoriatic arthritis in adults, and moderately to … , value-driven ustekinumab biosimilar. Biocon Biologics is committed to advancing … pharmacokinetics, efficacy, safety, and immunogenicity. Biocon Biologics highlighted the important safety …

… solution for intravenous infusion), Biocon Ltd said in a regulatory … high-quality biosimilars," Biocon Biologics CEO & Managing … of age), active psoriatic arthritis in adults, moderately to … through the "My Biocon Biologics" patient support …

… Biocon’s global footprint in biologics. Nepexto® targets conditions like rheumatoid arthritis … , psoriatic arthritis, plaque psoriasis, ankylosing … , and juvenile idiopathic arthritis by inhibiting tumor necrosis …

Bengaluru: Biocon’s biosimilars arm Biocon Biologics announced the launch of … diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and … brand in other markets soon. “Biocon Biologics is building on the …

… the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, … biosimilars business in 2022, Biocon Biologics has been strategically expanding … New Co Limited, a Biocon Biologics company. Aditya Bhagchandani …

… The denosumab biosimilars mark Biocon’s third and fourth … adults with active psoriatic arthritis or moderately to … 5). References 1. Biocon Biologics. Biocon Biologics Receives MHRA UK … 7, 2025. 5. Biocon Biologics. Biocon Biologics Receives MHRA Approval …

… biosimilar acceptance in treating psoriasis, arthritis, and Crohn’s disease. … reference biologic. References 1. Biocon Biologics. Biocon Biologics Receives MHRA Approval … Feb. 18, 2025. 5. Biocon Biologics. Biocon Biologics Completes Acquisition of Viatris …

… biosimilars company and subsidiary of Biocon received the approval from the … , and adults with active psoriatic arthritis or moderately to severely active …